摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 2-ethoxy-3-(4-aminophenyl)propanoate | 516504-19-1

中文名称
——
中文别名
——
英文名称
ethyl 2-ethoxy-3-(4-aminophenyl)propanoate
英文别名
ethyl 2-ethoxy-3-(4-aminophenyl)propionate;ethyl 3-(4-aminophenyl)-2-ethoxypropanoate
ethyl 2-ethoxy-3-(4-aminophenyl)propanoate化学式
CAS
516504-19-1
化学式
C13H19NO3
mdl
——
分子量
237.299
InChiKey
YSMNMUQGLPOPBO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    17
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    61.6
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    ethyl 2-ethoxy-3-(4-aminophenyl)propanoate1-(Methylsulfonyloxy)-2-[4-(methylsulfonyloxy)phenyl]ethanepotassium carbonate四丁基溴化铵 作用下, 以 甲苯 为溶剂, 反应 30.5h, 以44%的产率得到ethyl 2-ethoxy-3-[4-(4-methylsulfonyloxyphenethylamino)-phenyl]propionate
    参考文献:
    名称:
    Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
    摘要:
    本发明涉及具有化学式(I)的新型抗糖尿病、降血脂、抗肥胖和降胆固醇化合物,其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂化物以及含有它们的药学上可接受的组合物。
    公开号:
    US20030229083A1
  • 作为产物:
    描述:
    2-乙氧基-3-(4-硝基苯基)-丙烯酸乙酯 在 palladium 10% on activated carbon 氢气 作用下, 以 乙酸乙酯 为溶剂, 20.0 ℃ 、413.69 kPa 条件下, 以60%的产率得到ethyl 2-ethoxy-3-(4-aminophenyl)propanoate
    参考文献:
    名称:
    Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
    摘要:
    本发明涉及具有化学式(I)的新型抗糖尿病、降血脂、抗肥胖和降胆固醇化合物,其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂化物以及含有它们的药学上可接受的组合物。
    公开号:
    US20030229083A1
点击查看最新优质反应信息

文献信息

  • Novel compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
    申请人:Das Kumar Saibal
    公开号:US20050096331A1
    公开(公告)日:2005-05-05
    The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel alkyl carboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
    本发明涉及新型抗糖尿病、降脂、抗肥胖和降胆固醇化合物,它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。更具体地,本发明涉及一般式(I)的新型烷基羧酸、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。
  • Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
    申请人:Bhuniya Debnath
    公开号:US20050113368A1
    公开(公告)日:2005-05-26
    The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I) their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. More particularly, the present invention relates to novel alkyl carboxylic acids of the general, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them, to a process for preparing such compounds. The present invention also relates to processes for the preparation of the compounds of formula (I), novel intermediates, processes for their preparation, their use in the preparation of the above said compounds and their use as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds.
    本发明涉及公式(I)的新型抗糖尿病、降脂、抗肥胖和降胆固醇化合物及其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物,以及制备这些化合物的方法。更具体地说,本发明涉及一般的烷基羧酸及其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和包含它们的药学上可接受的组合物,以及制备这些化合物的方法。本发明还涉及公式(I)化合物的制备方法、新型中间体的制备方法、以及它们在制备上述化合物和作为抗糖尿病、降脂、抗肥胖和降胆固醇化合物的用途。
  • Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
    申请人:Debnath Bhunia
    公开号:US20070093476A1
    公开(公告)日:2007-04-26
    The present invention relates to novel compounds of formula (I) and their pharmaceutically acceptable salts, wherein ring “Ar 1 ” represents a monocyclic or polycyclic aromatic or partially saturated aromatic polycyclic, which may optionally contain up to 3 heteroatoms selected from N, S or O. The said monocyclic or polycyclic ring may be unsubstituted or have up to 4 substituents which may be identical or different; m and n independently represents an integer from 0 to 6; A represents O, S or bond; Y is selected from (CH 2 ) p′ (CH 2 ) p B(CH 2 ) q′ (CH 2 ) r B(CH 2 ) p D(CH 2 ) p′ where p, q and r each independently represents an integer from 0 to 6; B and D independently represents S, O, NR 4 or a bond, with a proviso that when B and D represents hereto atom p is not zero; R 4 represents hydrogen, alkyl, alkenyl, —S(O) 2 —R 8 or —C(O)R 8 where R 8 is alkyl, alkoxy; R 5 and R 6 independently represents hydrogen, alkyl, cycloalkyl or alkoxy; R 5 and R 6 together may form 3-8 membered cyclic ring which may optionally contains one or two hereto atoms selected from O, S or N; R 7 represents hydrogen, optionally substituted groups selected form alkyl, cycloalkyl, alkenyl or alkynyl. The present invention also relates to a process for preparation of compounds of formula (I), to pharmaceutical compositions containing compounds of formula (I) and their use in particular as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic agents.
    本发明涉及公式(I)的新化合物及其药学上可接受的盐,其中环“Ar1”表示单环或多环芳香或部分饱和芳香多环,可选含有最多3个选自N、S或O的杂原子。所述的单环或多环环可以未取代或具有最多4个相同或不同的取代基;m和n分别表示0到6的整数;A表示O、S或键;Y选自(CH2)p′(CH2)pB(CH2)q′(CH2)rB(CH2)pD(CH2)p′,其中p、q和r各自独立地表示0到6的整数;B和D分别表示S、O、NR4或键,条件是当B和D表示杂原子时,p不为零;R4表示氢、烷基、烯基、—S(O)2—R8或—C(O)R8,其中R8为烷基、烷氧基;R5和R6各自独立地表示氢、烷基、环烷基或烷氧基;R5和R6可以一起形成3-8成员环,该环可以选择性地包含选自O、S或N的一个或两个杂原子;R7表示氢、可选地从烷基、环烷基、烯基或炔基中选择的取代基。本发明还涉及公式(I)化合物的制备方法,含有公式(I)化合物的制药组合物以及其作为抗糖尿病、降脂、抗肥胖和降胆固醇药物的应用。
  • COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    申请人:Debnath Bhuniya
    公开号:US20070142470A1
    公开(公告)日:2007-06-21
    The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
    本发明涉及一种新型抗糖尿病、降脂、抗肥胖和降胆固醇的化合物,其化学式为(I),其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。
  • Novel beta-phenyl-alpha-oxysubstituted propionic derivatives: process for its preparation and their use in the preparation of pharmaceutically important compounds
    申请人:Bhuniya Debnath
    公开号:US20110105748A1
    公开(公告)日:2011-05-05
    The present invention relates to novel propionic acid derivatives. More particularly, the present invention relates to beta-phenyl alpha-oxysubstituted propionic acids of the general formula (I). The present invention also relates to processes for the preparation of compounds of the formula (I) and their use in the preparation of compounds of formula (II).
    本发明涉及新型丙酸衍生物。更具体地,本发明涉及一般式(I)的β-苯基α-氧代取代丙酸。本发明还涉及制备式(I)化合物的方法及其在制备式(II)化合物中的应用。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐